Danaher(US:DHR) ZACKS·2026-01-23 15:20Core Insights - Danaher (DHR) is expected to report quarterly earnings of $2.15 per share, reflecting a 0.5% increase year-over-year, with revenues forecasted at $6.79 billion, representing a 3.9% year-over-year increase [1] Earnings Estimates - The consensus EPS estimate has been revised upward by 0.4% in the past 30 days, indicating a reassessment by covering analysts [2] - Revisions to earnings estimates are significant indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock price performance [3] Revenue and Sales Forecasts - Analysts predict 'Total sales- Diagnostics' to be $2.70 billion, a 2.6% increase from the previous year [5] - The average forecast for 'Total sales- Life Sciences' is $2.06 billion, indicating a 1.2% increase year-over-year [5] - 'Total sales- Biotechnology' is expected to reach $2.02 billion, reflecting a 7.9% increase from the prior-year quarter [5] Operating Profit Estimates - 'Operating profit- Life Sciences' is projected to be $258.78 million, down from $376.00 million reported in the same quarter last year [6] - 'Operating profit- Biotechnology' is expected to reach $535.78 million, compared to $508.00 million reported in the same quarter last year [6] - 'Operating profit- Diagnostics' is forecasted at $690.13 million, up from $624.00 million reported in the same quarter last year [7] Stock Performance - Over the past month, Danaher shares have returned +3.7%, outperforming the Zacks S&P 500 composite's +0.6% change [7] - Danaher currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance in the near future [7]